Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.

Front Immunol

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Published: January 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649839	PMC
http://dx.doi.org/10.3389/fimmu.2021.800609	DOI Listing

Publication Analysis

commentary efficacy

efficacy safety

safety dupilumab

dupilumab moderate-to-severe

moderate-to-severe bullous

bullous pemphigoid

commentary

safety

dupilumab

moderate-to-severe

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!